Product Description
Cefmetazole is a second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefmetazole binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefmetazole)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: China | Korea | Russia | Taiwan | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hainan General Sanyo Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Surgical Wound Infection|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Lac-infection | N/A |
Recruiting |
Intraabdominal Infections|Communicable Diseases |
2023-07-01 |
|
| JMTO PREV07-01 | P3 |
Completed |
Colorectal Cancer |
2011-12-01 |
|
| C000000069 | P3 |
Completed |
Surgical Wound Infection |
None |